Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock

Roivant Sciences Ltd. (NASDAQ:ROIV) COO Eric Venker sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The stock was sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the sale, the chief operating officer now owns 617,470 shares in the company, valued at approximately $7,193,525.50. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Roivant Sciences Trading Down 0.9 %

NASDAQ ROIV opened at $11.62 on Thursday. The firm has a market capitalization of $8.58 billion, a price-to-earnings ratio of 2.30 and a beta of 1.24. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. Roivant Sciences Ltd. has a one year low of $8.24 and a one year high of $13.06. The company’s 50 day moving average price is $11.79 and its 200 day moving average price is $11.22.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The business had revenue of $55.10 million for the quarter, compared to the consensus estimate of $30.72 million. During the same quarter last year, the firm posted ($0.38) EPS. The business’s revenue for the quarter was up 155.1% compared to the same quarter last year. On average, sell-side analysts predict that Roivant Sciences Ltd. will post -1.14 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of ROIV. Mutual of America Capital Management LLC boosted its holdings in Roivant Sciences by 0.4% in the 2nd quarter. Mutual of America Capital Management LLC now owns 327,079 shares of the company’s stock worth $3,457,000 after acquiring an additional 1,142 shares during the period. Acadian Asset Management LLC grew its stake in Roivant Sciences by 23.2% during the 2nd quarter. Acadian Asset Management LLC now owns 8,510 shares of the company’s stock valued at $89,000 after purchasing an additional 1,603 shares in the last quarter. nVerses Capital LLC purchased a new stake in Roivant Sciences during the 2nd quarter worth approximately $34,000. DNB Asset Management AS raised its position in shares of Roivant Sciences by 6.4% in the 2nd quarter. DNB Asset Management AS now owns 56,022 shares of the company’s stock valued at $592,000 after purchasing an additional 3,386 shares in the last quarter. Finally, Point72 Hong Kong Ltd purchased a new position in shares of Roivant Sciences during the 2nd quarter valued at approximately $36,000. Institutional investors and hedge funds own 64.76% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the company. Cantor Fitzgerald restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Piper Sandler lifted their price target on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Wednesday, July 10th. HC Wainwright reiterated a “buy” rating and set a $18.00 price objective on shares of Roivant Sciences in a report on Thursday, September 19th. Finally, Bank of America raised their target price on shares of Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a research report on Wednesday, September 11th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $17.39.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.